- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02127476
A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease
May 31, 2017 updated by: Kyowa Hakko Kirin Pharma, Inc.
A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a single dose and as multiple doses in patients with Prodromal Alzheimer's Disease (AD) or Mild to Moderate AD.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
57
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gent, Belgium, 9000
- UZ Gent, De Pintelaan 185
-
-
-
-
-
Turku, Finland, FI-20520
- Clinical Research Services Turku (CRST), Itäinen Pitkäkatu 4B,
-
-
-
-
-
Amsterdam, Netherlands, 1081 GM
- Department of Neurology and Alzheimer Center, VU University Medical Center
-
Groningen, Netherlands, 9700 RB
- University Medical Centre Groningen (UMCG), Alzheimer Research Centre
-
-
-
-
-
Belgrade, Serbia, 11 000
- Clinical Centre of Serbia, Neurology Clinic, Dr Subotica Starijeg 6 ,
-
Belgrade, Serbia, 11 000
- Military Medical Academy, Crnotravska 17,
-
-
-
-
-
Malmö, Sweden, SE-205 02
- Memory Clinic, Malmo Minneskliniken, Memory Research Unit, Hs 33,
-
Mölndal, Sweden, SE-43141
- Sahlgrenska Gothenburg, Minnesmottagningen, Wallinsgatan 6
-
Stockholm, Sweden, SE-141 86
- Karolinska Stockholm Karolinska University Hospital, Huddinge, Dept. of Geriatrics/Memory Disorders Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
53 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with prodromal AD or mild to moderate AD
- Clinical Dementia Rating (CDR) score of 0.5, 1.0, or 2.0
- Have a cognitive impairment
- Low Aβ and high Tau in Cerebrospinal fluid (CSF)
- Mini Mental State Examination (MMSE) score > 16 at Screening
Exclusion Criteria:
- Previous active treatment with an AD immunotherapy in an investigational study
- Use of another investigational drug within 30 days of screening
- History or presence of clinically significant seizures, brain trauma, transient ischemic attack, and/or cerebrovascular disease
- Presence of a neurological condition that could be contributing to cognitive impairment above and beyond that caused by the subject's AD
- Evidence of infection, tumor, or other clinically significant lesions that could indicate a dementia diagnosis other than AD
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Single ascending dose and multiple ascending doses administration
|
Experimental: KHK6640
|
Single ascending dose and multiple ascending doses administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: Up to 7 months
|
Safety assessment variables will include all adverse events (AEs) including serious and non-serious AEs, laboratory parameters (hematology, chemistry, and urinalysis), vital signs, 12-lead electrocardiograms, physical and neurological examinations, and brain MRI
|
Up to 7 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2014
Primary Completion (Actual)
May 1, 2017
Study Completion (Actual)
May 1, 2017
Study Registration Dates
First Submitted
April 24, 2014
First Submitted That Met QC Criteria
April 28, 2014
First Posted (Estimate)
April 30, 2014
Study Record Updates
Last Update Posted (Actual)
June 1, 2017
Last Update Submitted That Met QC Criteria
May 31, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6640-001
- 2013-002873-23 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on KHK6640
-
Kyowa Kirin Co., Ltd.CompletedAlzheimer DiseaseJapan
-
Kyowa Kirin Co., Ltd.CompletedAlzheimer's DiseaseJapan